Research

If your care team recommends chemotherapy before stomach cancer surgery, you may wonder whether it makes surgery riskier. This study found that patients who received chemotherapy before surgery had similar complication rates, hospital stays, and survival as those who had surgery first—and were even less likely to be readmitted to the hospital after surgery.

HIPEC has moved from controversy toward becoming an important treatment option for carefully selected patients with advanced ovarian cancer. This editorial reviews the growing evidence showing improved survival without added long-term quality-of-life concerns and highlights why treatment at experienced CRS/HIPEC centers is so important.

Being told your cancer is "inoperable" may not be the end of the story. New research shows that many patients who sought a second opinion at a specialized peritoneal cancer center were ultimately able to undergo successful surgery. Learn why expert evaluation can open the door to additional treatment options—and why a second opinion could make all the difference.

Peritoneal metastases are difficult to treat because standard IV chemotherapy often cannot reach tumors inside the abdomen effectively. This review explores NIPS, an approach that combines intravenous chemotherapy with repeated chemotherapy delivered directly into the abdominal cavity. Early research—especially in gastric cancer—suggests this strategy may improve disease control, increase eligibility for surgery, and help some patients live longer.